Avivagen Announces Expansion of Non-Dilutive Financing in Support of Increased Product Sales
11/25/20, 3:04 PM
Location
ottawaAvivagen Inc. (TSXV:VIV, OTCQB:VIVXF) (“Avivagen” or the “Corporation”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhance and support immune function, thereby supporting general health and performance, announces that given the recent significant ramp up in placed orders for its OxC-beta Livestock™ and the upcoming launch of its human nutraceutical product, it has obtained additional debt financing of $350,000 through an unsecured Promissory Note from a Canadian Financial Institution. The financing is in addition to the $500,000 borrowed from the same lender on the same terms in October 2020.
Company Info
Location
ottawa, ohio, united states
Additional Info
Avivagen is a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications. By unlocking an overlooked facet of β-carotene activity, a path has been opened to safely and economically support immune function, thereby promoting general health and performance in animals. Avivagen is a public corporation traded on the TSX Venture and OTCQB® Venture Market exchanges under the symbols VIV and VIVXF, and is headquartered in Ottawa, Canada, based in partnership facilities of the National Research Council of Canada and Charlottetown, Prince Edward Island. For more information, visit www.avivagen.com. The contents of the website are expressly not incorporated by reference in this press release.